Carlos Nos
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.
Journal: Neurology
Published: August 20, 2026
"Low-Positive" MOG-IgG Cases Among Adults With a First Event Suggestive of Multiple Sclerosis.
Journal: Annals of clinical and translational neurology
Published: February 20, 2026
Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.
Journal: Annals of neurology
Published: September 01, 2025
Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.
Journal: Brain : a journal of neurology
Published: July 08, 2025
Uncovering alternative diagnoses in patients with clinical syndromes suggestive of multiple sclerosis: A transversal study from the prospective Barcelona CIS cohort.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 05, 2025
Age-Related Disability Outcomes After a First Demyelinating Event.
Journal: Neurology
Published: February 04, 2025
Deep learning to predict progression independent of relapse activity at a first demyelinating event.
Deep learning to predict progression independent of relapse activity at a first demyelinating event.
Journal: Brain communications
Published: December 17, 2024
The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational study.
Journal: The Lancet regional health. Europe
Published: December 17, 2024
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
Journal: Neurology
Published: December 03, 2024
Isolated CSF RT-QuIC positivity associates with a less aggressive disease course and decreased levels of neuronal/glial damage biomarkers in patients with sporadic Creutzfeldt-Jakob disease.
Journal: Journal of neurology
Published: September 19, 2024
SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis.
Journal: Therapeutic advances in neurological disorders
Published: April 17, 2024
Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 29, 2024
Last Updated: 09/26/2026